25 research outputs found
Humán papillomavírusok szerepe a szájüreg daganatos elváltozásaiban = Human papillomaviruses in oral cancers
Magyarországon a szájüregi rosszindulatú daganatok előfordulása és mortalitása kiemelkedően magas. Célkitűzésünk a humán papillomavírus (HPV) fertőzés szájüregi tumorgenezisben játszott etiológiai szerepének és prognosztikai indikátorként való alkalmazhatóságának vizsgálata volt, emellett vizsgáltuk a p53 tumorszuppresszor gén 72 kodont érintő polimorfizmusának és mutációinak, valamint az 1. genocsoportú torque-tenovírus (g1TTV) prognosztikai szerepét is. Mintáink 65 orális laphámrákos (OSCC), 44 orális leukoplakiában és 119 orális lichen planusban szenvedő betegtől származtak, a kontroll populációt 72 egészséges személy képezte. A HPV prevalenciája a lézió súlyosságával nőtt, szignifikánsan magasabb volt minden betegcsoportban, mint a kontrollban, főképpen magas kockázatú genotípusokat találtunk. Emellett a HPV jelenléte a tumor lokalizációjával illetve kémiai karcinogénekkel (alkohol, dohányzás) együttesen hatva a OSCC rossz pronózisával és a betegek rosszabb túlélésével társult. A g1TTV és a p53 gén polimorfizmusa és mutációi nem befolyásolták az OSCC prognózisát. A projekt adatai alátámasztják a HPV etiológiai szerepét a OSCC kialakulásában, emellett azt mutatják, hogy a prekancerózisok kialakulásában is szerepet játszhat. Igazoltuk, hogy a HPV jelenléte kockázati tényezőként szerepel a rossz prognózisú tumorok kialakulása során, tehát a HPV kimutatása segítséget nyújthat a prognózis megállapításában és az utókezelés tervezésében. | Morbidity and mortality due to oral squamous cell carcinoma (OSCC) is high in Hungary. The aim of the project was to investigate the role of human papillomaviruses (HPVs) in the etiology of OSCC as well as its prognostic value. Besides HPVs we also examined the prognostic significance of genogroup 1 torque-tenovirus (g1TTV) and the mutations and codon 72 polymorphism of p53 tumour suppressor gene. Study population consisted of 65 OSCC, 44 oral leukoplakia and 119 oral lichen planus patients, buccal epithelial cells from 72 healthy individuals were used as a control. Prevalence of HPV increased gradually with the increasing severity of the lesion, it was significantly higher in all patients groups compared to the control. We detected mainly high-risk genotypes. Presence of HPV synergistically with unfavourable tumour localization and chemical carcinogens (alcohol consumption, smoking) led to higher risk of poor prognosis and shorter survival. Presence of g1TTV and p53 gene mutations and polymorphism did not later the prognosis significantly. Our data accord with etiologic role of HPVs in OSCC, and indicate that HPVs may play a role in the development of oral precanceroses as well. We proved that presence of HPV may serve as a risk factor for tumours with poor prognosis, therefore it can be used as a prognostic indicator and may aid in planning adjuvant therapy
Effects of substrate, ceramic thickness, translucency, and cement shade on the color of CAD/CAM lithium-disilicate crowns
The aim of this in vitro study was to evaluate the effects of substrate colors, different levels of ceramic thickness and translucency, and cement shades on the color difference from a reference color of lithium-disilicate crowns.A premolar tooth preparation was made on a study model for 1.0 and 1.5 mm thick full-ceramic crowns. Digital impressions were taken (3Shape TRIOS) and crowns designed in a CAD program (DentalDesigner). Shade A1 crowns were milled (Everest, Kavo) from high-translucency (HT) and low-translucency IPS e.max (Ivoclar Vivadent) blocks. Twelve substrates were made of different colors and materials (Natural Die Material, Co-Cr, zirconia, and gold-colored alloy). Three different shades of try-in pastes were used to simulate the effect of cements (Variolink Esthetic try-in paste; Ivoclar). Shade measurement was done three times for each crown by a spectrophotometer (VITA Easyshade Advance); averages were compared to a reference crown (A1, HT, 1.5 mm, ND2 abutment, neutral try-in paste) with ΔE00 (CIEDE2000, according to the CIE latest standard) calculated.All the examined parameters influenced the ΔE00 of the crowns. The weakest effect was exerted by the try-in paste.All examined parameters influenced the final color of e.max CAD lithium-disilicate ceramic crowns.Matching the shade of ceramic crowns to the natural tooth color is a great challenge in dentistry. To meet patients' increasing esthetical expectations, CAD/CAM methods are very popular for full-ceramic crowns. However, several factors such as the shade of the abutment, luting cement color, ceramic thickness, and translucency may influence the final color. Our objective was to measure the optical effect of these factors on the final shade of CAD/CAM lithium-disilicate ceramic crowns
A város peremén. (A rozsdaövezet múltja és jelene Budapesten) = At the outskirts of the city. (Past and Present of the brownfield area in Budapest)
A barnamezős térség - ahol korábban elsősorban ipari tevékenység folyt - felméréseink szerint 68-70 km2-t foglal el Budapest közigazgatási területéből. Kutatásaink négy területre koncentrálódtak: bemutattuk az ipar mintegy 160 éves történetét, az ipari múlt örökségét (a környezeti szennyezettséget, az alacsony hatásfokú földhasználatot, a megüresedett területeket, a zavaros tulajdonviszonyokat, stb.), a korábbi funkciók spontán változásait (az új bevásárló központok, technológiai és ipari parkok megjelenését, az ipari műemlékek más célú - kulturális, lakás, stb. - felhasználását), és végül, a barnamezős területek rehabilitációjával foglalkozó, reménykeltő terveket. A barnamező megújítására irányuló erőfeszítések előtt hatalmas a kihívás. Mindazonáltal, ez a térség Budapest fejlesztésének fontos gazdasági tartaléka. | The brownfield belt of the Hungarian capital, where once large industrial production sites were located, comprises an area of 68-70 square kilometres. Our researches have been concentrated on four fields: to present the 160-year-long history of Budapest as an industrial city; the legacy of the industrial past (environmental pollution, the uneffected land use, empty areas, a messy ownership, etc.); the spontaneous changes of the former fuctions (appearence of new shopping centres, technological and industrial parks, industrial monuments used for cultural events, housing, etc.); and finally the promising plans that deal with the brownfields of Budapest. Any effort of brownfield rehabilitation in Budapest faces formidable challenges. However, this area could be promising for metropolitan development and become an important economic factor in the future
Less marginal bone loss around bone-level implants restored with long abutments: A systematic review and meta-analysis.
The aim of this study was to investigate the biological outcomes of bone-level implants restored with long vs. short abutments, with regard to the 'one abutment at one time' protocol. The systematic search was performed in five databases: MEDLINE (PubMed), EMBASE, Web of Science, Scopus, and CENTRAL for randomized controlled trials up to January 14, 2023. Data were collected for marginal bone loss, bleeding on probing, and probing pocket depth by two reviewers. As effect size measure, mean difference (MD), and risk ratio (RR) were used for continuous and categorical outcomes, R-statistics software was used for conducting statistical analyses. For quality and certainty assessment, Risk of Bias Tool 2, ROBINS-I, and GRADE approach were used. The search resulted in 4055 records without any duplicates. After title, abstract, and full-text analysis, eight articles were found eligible for inclusion. Bone-level and platform-switched implants presented less marginal bone loss after 6 months and 1 year as well, when long abutments were used (MD 0.63, 95% CI: [-0.16; 1.42]) and (MD 0.26, 95% CI: [-0.02; 0.53]). However, subgroup analysis revealed no difference in marginal bone loss when applying 'one abutment at one time' protocol (p = 0.973). Bleeding on probing and probing pocket depth presented similarly good results in both groups without almost any differences (RR 0.97, 95% CI: [0.76; 1.23]) and (MD -0.05, 95% CI: [-1.11; 1.01]). Longer abutments on bone-level implants seem to be a favorable choice for decreasing early marginal bone loss, irrespective of connection timing
Incidence and predictors of heart failure with improved ejection fraction category in a HFrEF patient population
Hemokinin-1 as a Mediator of Arthritis-Related Pain via Direct Activation of Primary Sensory Neurons
The tachykinin hemokinin-1 (HK-1) is involved in immune cell development and inflammation, but little is known about its function in pain. It acts through the NK1 tachykinin receptor, but several effects are mediated by a yet unidentified target. Therefore, we investigated the role and mechanism of action of HK-1 in arthritis models of distinct mechanisms with special emphasis on pain. Arthritis was induced by i.p. K/BxN serum (passive transfer of inflammatory cytokines, autoantibodies), intra-articular mast cell tryptase or Complete Freund’s Adjuvant (CFA, active immunization) in wild type, HK-1- and NK1-deficient mice. Mechanical- and heat hyperalgesia determined by dynamic plantar esthesiometry and increasing temperature hot plate, respectively, swelling measured by plethysmometry or micrometry were significantly reduced in HK-1-deleted, but not NK1-deficient mice in all models. K/BxN serum-induced histopathological changes (day 14) were also decreased, but early myeloperoxidase activity detected by luminescent in vivo imaging increased in HK-1-deleted mice similarly to the CFA model. However, vasodilation and plasma protein extravasation determined by laser Speckle and fluorescent imaging, respectively, were not altered by HK-1 deficiency in any models. HK-1 induced Ca2+-influx in primary sensory neurons, which was also seen in NK1-deficient cells and after pertussis toxin-pretreatment, but not in extracellular Ca2+-free medium. These are the first results showing that HK-1 mediates arthritic pain and cellular, but not vascular inflammatory mechanisms, independently of NK1 activation. HK-1 activates primary sensory neurons presumably via Ca2+ channel-linked receptor. Identifying its target opens new directions to understand joint pain leading to novel therapeutic opportunities
Hemokinin-1 induces transcriptomic alterations in pain-related signaling processes of rat primary sensory neurons independently of NK1 tachykinin receptor activation
Lacking ARHGAP25 Mitigates the Symptoms of Autoantibody-induced Arthritis in Mice
Objective: Despite intensive research on rheumatoid arthritis, the pathomechanism of the disease is still not fully understood and the treatment has not been completely resolved. Previously we demonstrated that the GTPase-activating protein, ARHGAP25 has a crucial role in the regulation of basic phagocyte functions. Here we investigate the role of ARHGAP25 in the complex inflammatory process of autoantibody-induced arthritis. Methods: Wild-type and ARHGAP25 deficient (KO) mice on a C57BL/6 background, as well as bone marrow chimeric mice, were treated i.p. with the K/BxN arthritogenic or control serum, and the severity of inflammation and pain-related behavior was measured. Histology was prepared, leukocyte infiltration, cytokine production, myeloperoxidase activity, and superoxide production were determined, and comprehensive western blot analysis was conducted. Results: In the absence of ARHGAP25, the severity of inflammation, joint destruction, and mechanical hyperalgesia significantly decreased, similarly to
phagocyte infiltration, IL-1b, and MIP-2 levels in the tibiotarsal joint, whereas superoxide production or myeloperoxidase activity was unchanged. We observed a significantly mitigated phenotype in KO bone marrow chimeras as well. In addition, fibroblast-like synoviocytes showed comparable expression of ARHGAP25 to neutrophils. Significantly reduced ERK1/2, MAPK, and I-kB protein
signals were detected in the arthritic KO mouse ankles. Conclusion: Our findings suggest that ARHGAP25 has a key role in the pathomechanism of autoantibody-induced arthritis in which it regulates inflammation via the I-kB/NF-kB/IL-1b axis with the involvement of both immune cells and fibroblast-like synoviocytes
Magyar Szívelégtelenség Regiszter 2015–2016. Kezdeti eredmények | Hungarian Heart Failure Registry 2015–2016. Preliminary results
Absztrakt:
A szívelégtelenség az elmúlt évtizedek jelentős terápiás fejlődése ellenére is
rossz prognózisú és különösen a nagyszámú kórházi felvétel miatt igen magas
költségigényű kórkép. Mindezek miatt a magas szakmai színvonalú ellátás alapvető
érdeke a betegeknek, az ellátóknak és a finanszírozóknak egyaránt. Egy adott
kórkép vonatkozásában az ellátási színvonal értékelésének legjobb módszerét a
betegségspecifikus regiszterek jelentik. Mind ez ideig Magyarországon a
szívelégtelenségben szenvedő betegek jellemzőit, ellátását értékelő regiszter
nem volt. E hiány pótlására hozta létre a Magyar Kardiológusok Társasága a
Magyar Szívelégtelenség Regisztert. Jelen közlemény célja a regiszter céljainak,
módszertanának, működésének és első éves eredményeinek bemutatása. A regiszter
célja egy korszerű, internetalapú adatbázis kialakítása, ami nagyszámú,
aktuálisan vagy korábban szívelégtelenség miatt kórházi felvételre került,
illetve aktuálisan vagy korábban súlyos szívelégtelenség (NYHA III–IV.) miatt
ambuláns ellátásban részesült beteg adatait összegzi. A regiszter kialakításában
jelenleg 17 kardiológiai osztály vesz részt. A tervezett betegszám 2000. A
betegeket első lépésben egy évig tervezzük követni (pilot vizsgálat), majd ezt
követően, a megfelelő tapasztalatok értékelése után, hosszú távú követést
tervezünk. A regiszterben adatokat gyűjtünk a szívelégtelenség típusára
(csökkent – LVEF≤45% – vs. megtartott ejekciós – LVEF>45% – frakciójú
szívelégtelenség), etiológiájára, a komorbiditásokra, a diagnózishoz felhasznált
vizsgálatokra, a kezelés során alkalmazott terápiás módszerekre, valamint a
hospitalizációra és a mortalitásra vonatkozóan. Az első év során a regiszterbe
bevont 698 beteg kiindulási adatait értékelve azt láttuk, hogy a betegek
többsége (87,8%) csökkent ejekciós frakciójú szívelégtelenségben szenved,
39,8%-ban a szívelégtelenség hátterében coronariabetegség áll, a társbetegségek
közül leggyakoribb a hypertonia, ezt követik a diabetes mellitus, a
veseelégtelenség és a COPD. A betegek 94,4%-a kapott ACE-gátlót vagy
angiotenzinreceptor-blokkolót, 95,9%-a béta-receptor-blokkolót és 73,9%-a
mineralokortikoidreceptor-antagonistát. A neurohormonális antagonista
készítmények átlagos dózisa minden szer esetében meghaladta az irányelvekben
meghatározott céldózisok felét. A kardiális reszinkronizációs kezelés
alkalmazása 11,7%-os, az implantálható cardioverter defibrillátorral élők aránya
25,8% volt. A Magyar Szívelégtelenség Regiszterbe eddig bevont betegek
gyógyszeres és eszközös kezelése megfelel az aktuális irányelvek előírásainak.
Ez azonban minden bizonnyal nem azt jelenti, hogy hazánkban a
szívelégtelenség-ellátással nincs probléma, hanem azt, hogy a szívelégtelenség
kezelése iránt elkötelezett kardiológiai osztályokon az irányelveknek megfelelő
szívelégtelenség-gondozással magas színvonalú betegellátás érhető el. Orv.
Hetil., 2017, 158(3), 94–100.
|
Abstract:
Heart failure is associated with a poor prognosis despite significant advances in
the pharmacological and device therapy and incurs very high cost because of
frequent hospitalizations. Therefore, professional high-quality care is
essential for both patients and the healthcare system. The best way to evaluate
the quality of care for a particular disease is the use of disease-specific
registries. Until now, there has not been a registry evaluating characteristics
and management of heart failure patients in Hungary. For that reason, the
Hungarian Society of Cardiology initiated the set-up of the Hungarian Heart
Failure Registry. The Aim of this paper is to present the goals, methods and
first year results of the Hungarian Heart Failure Registry. The goal of the
Registry is to create a modern, web-based database that summarizes the data of
large number of patients who are currently or were previously admitted to
hospital or who are currently or were previously patients in an outpatient
department due to severe heart failure (NYHA III–IV). Currently 17 cardiology
departments participate in the development of the Registry. The planned number
of patients is 2000. Initially follow-up was planned for one year (pilot study).
After the evaluation of the relevant experiences of the pilot study, long-term
follow-up is planned. The Registry collects information about the type of heart
failure (heart failure with reduced – LVEF≤45% – vs. preserved – LVEF>45% –
ejection fraction), etiology, co-morbidities, diagnostic methods, treatment as
well as morbidity and mortality. After the first year, assessing the baseline
parameters of 698 patients enrolled in the Registry we found that the majority
of patients (87.8%) has heart failure with reduced ejection fraction and in
39.8% of the patients heart failure has an ischaemic origin. The most frequent
co-morbidity was hypertension followed by diabetes, renal insufficiency and
COPD. The patients were treated with ACE inhibitors or ARBs in 94.4%, with beta
blockers in 95.9%, and mineralocorticoid receptor antagonists in 73.9%. The mean
dose of neurohormonal antagonists was higher than half of the target dose
defined by current guidelines. The use of cardiac resynchronisation therapy was
11.7% and implantable cardioverter defibrillator was 25.8%. The pharmacological
and device therapy of patients who were enrolled in the Registry until now was
fit the current guidelines’ recommendations. This, however, does not mean that
the management of heart failure is without problems in our country but that high
quality patient care is available with adequate heart failure treatment in
cardiology departments dedicated to heart failure care. Orv. Hetil., 2017,
158(3), 94–100